ATE151644T1 - Anthracyclinkonjugate - Google Patents

Anthracyclinkonjugate

Info

Publication number
ATE151644T1
ATE151644T1 AT91920862T AT91920862T ATE151644T1 AT E151644 T1 ATE151644 T1 AT E151644T1 AT 91920862 T AT91920862 T AT 91920862T AT 91920862 T AT91920862 T AT 91920862T AT E151644 T1 ATE151644 T1 AT E151644T1
Authority
AT
Austria
Prior art keywords
formula
residue
anthracycline
conjugates
moiety
Prior art date
Application number
AT91920862T
Other languages
English (en)
Inventor
Francesco Angelucci
Daniella Ruggieri
Stefania Stefanelli
Antonino Suarato
Laura Bersani
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Application granted granted Critical
Publication of ATE151644T1 publication Critical patent/ATE151644T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Catching Or Destruction (AREA)
AT91920862T 1990-12-05 1991-12-03 Anthracyclinkonjugate ATE151644T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026491A GB9026491D0 (en) 1990-12-05 1990-12-05 Anthracycline-conjugates

Publications (1)

Publication Number Publication Date
ATE151644T1 true ATE151644T1 (de) 1997-05-15

Family

ID=10686550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91920862T ATE151644T1 (de) 1990-12-05 1991-12-03 Anthracyclinkonjugate

Country Status (22)

Country Link
EP (1) EP0514515B1 (de)
JP (1) JP3169223B2 (de)
KR (1) KR100249067B1 (de)
AT (1) ATE151644T1 (de)
AU (1) AU649506B2 (de)
CA (1) CA2075288C (de)
DE (1) DE69125707T2 (de)
DK (1) DK0514515T3 (de)
ES (1) ES2103317T3 (de)
FI (1) FI103765B (de)
GB (1) GB9026491D0 (de)
GR (1) GR3024050T3 (de)
HU (2) HU221857B1 (de)
IE (1) IE914211A1 (de)
IL (2) IL114303A (de)
MX (1) MX9102357A (de)
MY (1) MY107821A (de)
NZ (1) NZ240827A (de)
PT (1) PT99675B (de)
RU (1) RU2107690C1 (de)
WO (1) WO1992010212A1 (de)
ZA (1) ZA919562B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
AU729643B2 (en) * 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
RU2196604C1 (ru) 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
CN102159248B (zh) * 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK160616C (da) * 1979-02-03 1991-09-02 Zaidan Hojin Biseibutsu Fremgangsmaade til fremstilling af anthracyclinderivater eller syreadditionssalte deraf
JPS56156300A (en) * 1980-04-26 1981-12-02 Microbial Chem Res Found Novel preparative method of anthracyclin derivative
GB2172594B (en) * 1985-03-22 1988-06-08 Erba Farmitalia New morpholino derivatives of daunorubicin and doxorubicin
EP0318948B1 (de) * 1987-12-02 1992-08-19 Neorx Corporation Spaltbare Immun-Conjugate für die Abgabe und Freisetzung von Agenzien in natürlicher Form
FI102355B (fi) * 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
DE68919366T2 (de) * 1988-09-30 1995-05-18 Neorx Corp Spaltbare linker zur reduzierung der akkumulierung von immunokonjugaten in nicht-zielorganen.
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten

Also Published As

Publication number Publication date
MY107821A (en) 1996-06-29
HU221857B1 (hu) 2003-02-28
ES2103317T3 (es) 1997-09-16
JPH05503717A (ja) 1993-06-17
PT99675A (pt) 1992-10-30
MX9102357A (es) 1992-10-01
IL114303A0 (en) 1995-10-31
DE69125707D1 (de) 1997-05-22
GB9026491D0 (en) 1991-01-23
AU649506B2 (en) 1994-05-26
IL100218A (en) 1996-07-23
IL100218A0 (en) 1992-09-06
DE69125707T2 (de) 1997-09-11
FI923499A0 (fi) 1992-08-03
KR100249067B1 (ko) 2000-04-01
JP3169223B2 (ja) 2001-05-21
IE914211A1 (en) 1992-06-17
ZA919562B (en) 1992-08-26
HU9202544D0 (en) 1992-10-28
EP0514515B1 (de) 1997-04-16
KR920703115A (ko) 1992-12-17
WO1992010212A1 (en) 1992-06-25
CA2075288C (en) 2004-02-17
RU2107690C1 (ru) 1998-03-27
FI923499A (fi) 1992-08-03
HU222114B1 (hu) 2003-04-28
IL114303A (en) 1997-09-30
NZ240827A (en) 1993-12-23
AU9023191A (en) 1992-07-08
HU9602873D0 (en) 1996-12-30
HUT63171A (en) 1993-07-28
FI103765B1 (fi) 1999-09-30
EP0514515A1 (de) 1992-11-25
PT99675B (pt) 1999-05-31
FI103765B (fi) 1999-09-30
CA2075288A1 (en) 1992-06-06
DK0514515T3 (da) 1997-05-12
GR3024050T3 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
ATE135919T1 (de) Linker für bioaktive mittel
ATE257014T1 (de) Lichtbilderzeugungskontrastmitteln
KR950007875A (ko) 프로-프로드럭, 이의 제조방법 및 용도
DE69125707T2 (de) Anthracyclinkonjugate
ES2095840T3 (es) Conjugado de anticuerpo-farmaco.
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
ATE177110T1 (de) Verbesserte b12-konjugate
SE8702409L (sv) Nya antracykliner
ATE72445T1 (de) 4'-epi-4'-aminoanthracycline.
GR3006831T3 (de)
ATE313536T1 (de) Tetracyclische acetale
IT1270817B (it) Coniugati di farmaci antivirali ad attivita' epatotropica, relativi veicolanti e composizioni farmaceutiche che li contengono
EA200000025A1 (ru) 13-дигидро-3'-азиридиноантрациклины
IT1256420B (it) Bassi polimeri dell'n-acriloilmorfolina monofunzionalizzati ad un estremo e loro coniugati con enzimi e farmaci
TW332816B (en) Peptide and carbohydrate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee